EUCTR2006-005003-33-GB进行中（未招募）1 期
Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi.
Astellas Global Pharma Development, Inc0 个研究点目标入组 149 人开始时间: 2007年11月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 149
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Patients with proven/probable invasive fungal disease caused by Aspergillus who also have renal impairment (including dialysis)
- •2. Patients with proven/probable invasive fungal disease caused by rare moulds, yeasts and dimorphic fungi, whether really impaired or not (including dialysis)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A known condition of the patient that may jeopardize adherence to the protocol requirements
- •2. Patients who are unlikely to survive 30 days
- •3. Patients with a body weight < 40 kg
- •4. Women who are pregnant or breastfeeding
研究者
相似试验
进行中（未招募）
不适用
Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi.Invasive fungal disease caused by Aspergillus species and Candida strains in patients with renal impairment as well as disease caused by rare moulds, yeats or dimorphic fungi.MedDRA version: 9.1Level: HLTClassification code 10003486Term: Aspergillus infectionsMedDRA version: 9.1Level: LLTClassification code 10049160Term: CandidaemiaEUCTR2006-005003-33-CZBasilea Pharmaceutica Ltd100
进行中（未招募）
不适用
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiEUCTR2006-005003-33-HUAstellas Pharma Global Development, Inc.150
进行中（未招募）
不适用
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiInvasive fungal disease caused by Aspergillus species in patients with renal impairment as well as disease caused by rare moulds, yeasts or dimorphic fungi.MedDRA version: 14.1Level: HLTClassification code 10003486Term: Aspergillus infectionsSystem Organ Class: 100000004862EUCTR2006-005003-33-DEAstellas Global Pharma Development, Inc360
进行中（未招募）
1 期
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare FungiEUCTR2006-005003-33-BEAstellas Global Pharma Development, Inc.360
已完成
3 期
A clinical trial to study the effect of Isavuconazole in patients with Aspergillosis and Renal Impairment or of Patientswith Invasive Fungal Disease Caused by Rare Molds,Yeasts or Dimorphic Fungi.CTRI/2012/01/002352Astellas Pharma Global Development Inc APGD100